Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05075603 · ClinicalTrials.gov registry record · Phase 1
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
A Phase 1 study, sponsored by NeoImmuneTech.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05075603 is a Phase 1 study that has completed, run by NeoImmuneTech. The registered enrollment target is 17 participants.
The verdict
NCT05075603, a Phase 1 study, has completed, sponsored by NeoImmuneTech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.
Interventions
- DRUG Tisagenlecleucel
- DRUG Efineptakin alfa
- DRUG Axicabtagene ciloleucel
- DRUG Lisocabtagene Maraleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2025-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05075603
The ClinicalTrials.gov registry entry for NCT05075603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeoImmuneTech, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tisagenlecleucel is the first listed.
NCT05075603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05075603 about?
NCT05075603 is a clinical study titled "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy". This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.
What is the current status of trial NCT05075603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-08-06. Estimated completion is 2025-03-12.
What interventions are being tested in trial NCT05075603?
The interventions under investigation include: Tisagenlecleucel (DRUG), Efineptakin alfa (DRUG), Axicabtagene ciloleucel (DRUG), Lisocabtagene Maraleucel (DRUG).
Who is sponsoring clinical trial NCT05075603?
This trial is sponsored by NeoImmuneTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.